In vivo assessment of pharmacokinetic interactions of empagliflozin and henagliflozin with sorafenib: an animal-based study

QR Code

In vivo assessment of pharmacokinetic interactions of empagliflozin and henagliflozin with sorafenib: an animal-based study

Background Sorafenib is a multi-targeted tyrosine kinase inhibitor (TKI) used for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma (HCC), and radioactive iodine-resistant thyroid carcinoma. Notably, glucose transporters sodium-glucose cotransporter 2 (SGLT2) and glucose trans...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wenyu Du, Zihan Liu, Zhi Wang, Xin Zhou, Zhanjun Dong, Ying Li
Format:	Article
Language:	English
Published:	PeerJ Inc. 2025-07-01
Series:	PeerJ
Subjects:	Hepatocellular carcinoma Type 2 diabetes mellitus Sorafenib Empagliflozin Henagliflozin Drug–drug interaction
Online Access:	https://peerj.com/articles/19662.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Decoding Drug Interactions: Character and Degree of Pharmacokinetic Interactions Between Telmisartan and Sorafenib or Donafenib in Rats
by: Li Y, et al.
Published: (2025-07-01)

Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway
by: Qing-Feng Xiang, et al.
Published: (2019-12-01)

Successful two-stage operation for esophageal necrosis due to proton beam therapy followed by sorafenib in a case of large hepatocellular carcinoma
by: Eiji Higaki, et al.
Published: (2020-06-01)

PHARMACOECONOMICAL RESEARCH OF THE USE OF SORAFENIB IN MALIGNANT TUMORS
by: M. Y. Frolov, et al.
Published: (2016-09-01)

ATF7IP inhibits Sorafenib-induced ferroptosis in hepatocellular carcinoma cells by inhibiting CYB5R2 transcription and stabilizing PARK7 protein
by: Yijie Su, et al.
Published: (2025-09-01)

Tyrosine kinase inhibitors were well-tolerated among patients with different etiologies of advanced HCC with lower survival in non-viral patients
by: Eman M. F. Barakat, et al.
Published: (2025-06-01)

SMYD2 epigenetically activates BMP4/SMAD1/5/8/ID3 axis to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma
by: Shanshan Wang, et al.
Published: (2025-09-01)

Antitumor activity of sorafenib on colorectal cancer
by: Turgut Kacan, et al.
Published: (2016-08-01)

An Fe(III)-covalent organic framework (COF)–sorafenib nanoplatform induces chemo-ferroptosis for enhanced hepatocellular carcinoma immunotherapy
by: Binglong Bai, et al.
Published: (2025-10-01)

Cost-utility analysis of empagliflozin compared with dapagliflozin in patients with type 2 diabetes in China
by: Huiyuan Zhang, et al.
Published: (2025-07-01)

Sorafenib induces ferroptosis in human renal cell carcinoma cells through CCAT/enhancer-binding protein homologous protein
by: Dinh Thi Nhung, et al.
Published: (2025-09-01)

Assessing the Efficacy and Safety of Dapagliflozin and Empagliflozin as an Add-on Therapy for Lowering Glycated Hemoglobin and Weight in Type 2 Diabetes Mellitus Patients
by: Mahima Makhija, Alka Bansal, Lokendra Sharma, Punam Jakhar, Susheel Kumar, Ashish Agrawal
Published: (2025-06-01)

THE USE OF SORAFENIB (NEXAVAR) IN TREATMENT OF PATIENT WITH DISSEMINATED PARATHYROID CANCER: A CASE REPORT
by: V. A. Gorbunova, et al.
Published: (2017-04-01)

Empagliflozin Repurposing for Lafora Disease: A Pilot Clinical Trial and Preclinical Investigation of Novel Therapeutic Targets
by: Giuseppe d’Orsi, et al.
Published: (2025-05-01)

Approaches to conducting a physiologically relevant test (PRT) in the study of medicines containing substance IIc of the BCS subclass using sorafenib as an example
by: A. V. Suvorova, et al.
Published: (2024-09-01)

Efficacy and safety of empagliflozin in patients over 65 with type 2 diabetes mellitus complicating cardiorenal syndromes type II and IV
by: Cao Mugen, et al.
Published: (2025-01-01)

Development of Green RP-HPLC method for determination of sorafenib in film-coated tablets
by: Sanija Zulfikjari, et al.
Published: (2024-12-01)

Initiating Empagliflozin and Sacubitril/Valsartan Early After Acute Myocardial Infarction: Mechanistic Study
by: Daina Martínez‐Falguera, et al.
Published: (2025-06-01)

Co-Assembled Nanoparticles Comprising Sorafenib and Hederagenin Derivative for Enhanced Anti-Hepatic Fibrosis Activity
by: Lu M, et al.
Published: (2025-07-01)

Clinical Efficacy and Safety of Empagliflozin in Patients with Acute Heart Failure from the First Day of Hospitalization
by: D. P. Golubovskaya, et al.
Published: (2023-05-01)

Experience of Hepatocellular Cancer Therapy with Multikinase Inhibitors in the Republic of Bashkortostan
by: Sh. Kh. Gantsev, et al.
Published: (2020-11-01)

Single-Cell RNA Sequencing Integrated with Bulk-RNA Sequencing Analysis Reveals Prognostic Signatures Based on PANoptosis in Hepatocellular Carcinoma
by: Wang J, et al.
Published: (2025-07-01)

Clinical and economic analysis of empagliflozin therapy in patients with heart failure across the ejection fraction range
by: S. V. Nedogoda, et al.
Published: (2023-07-01)

Emerging trends and knowledge networks in pan-cancer sorafenib resistance: a 20-year bibliometric investigation
by: Qiong Zhou, et al.
Published: (2025-07-01)

Co-delivery of sorafenib and VEGF-siRNA via pH-sensitive liposomes for the synergistic treatment of hepatocellular carcinoma
by: Yao Yao, et al.
Published: (2019-12-01)

Risk of hepatocellular carcinoma in adults exposed to oral antidiabetic drugs: a systematic review
by: Shadman Newaz, et al.
Published: (2025-06-01)

Thyroid follicular carcinoma complicating with skin metastasis
by: Ali Alkan, et al.
Published: (2016-08-01)

LOW DOSE CYTARABINE PLUS SORAFENIB IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA
by: Tural Mahmudov
Published: (2025-07-01)

Glycogen storage disease type Ib: modern understanding of the pathogenesis of neutropenia and prospects for its treatment with empagliflozin
by: Andrej N. Surkov, et al.
Published: (2023-11-01)

Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial
by: Yu. M. Lopatin, et al.
Published: (2022-04-01)

PENGARUH PEMBERIAN EKSTRAK DAUN SIRSAK TERHADAP DERAJAT HISTOPATOLOGI PADA TIKUS WISTAR KARSINOMA HEPATOSELULER YANG MENDAPAT TERAPI STANDAR SORAFENIB
by: Nanda Putri Mardiana Sinaga, et al.
Published: (2019-10-01)

Optimal sequencing of locoregional and systemic therapies for intermediate and advanced hepatocellular carcinoma: a network meta-analysis
by: Wei Lu, et al.
Published: (2025-06-01)

Effects of Empagliflozin on Sarcopenia Risk, Body Composition, and Muscle Strength in Type 2 Diabetes: A 24-Week Real-World Observational Study
by: Deniz Çetin, et al.
Published: (2025-06-01)

Empagliflozin: a path from glycemic control to reduced cardiovascular mortality and heart failure-related hospitalizations
by: N. R. Khasanov
Published: (2022-02-01)

Harnessing multi-omics and artificial intelligence: revolutionizing prognosis and treatment in hepatocellular carcinoma
by: Zhen Wang, et al.
Published: (2025-07-01)

Mechanisms of hepatitis B virus X protein in progression and drug resistance of hepatocellular carcinoma
by: Zhou Ping, et al.
Published: (2025-06-01)

CLINICAL EXPERIENCE OF NEXAVAR (SORAFENIB) APPLICATION IN PATIENTS WITH METASTATIC DIFFERENTIATED THYROID CANCER RESISTANT TO THERAPY 131I
by: P. A. Isaev, et al.
Published: (2015-04-01)

Antimycobacterial and immunomodulatory activities of sorafenib in a preclinical mouse model of TB infection through CD4+CD25low and CD8+CD25low effector T cells
by: Raju S. Rajmani, et al.
Published: (2025-07-01)

Cardiovascular death risk reduction in type 2 diabetes patients with confirmed cardiovascular diseases
by: Е. V. Shlyakhto, et al.
Published: (2018-09-01)

Comparative efficacy study of experimental chronic heart failure
by: D. Yu. Ivkin, et al.
Published: (2025-03-01)